News Search Results
Aug 18, 2025, 17:00 ET REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
which has been shown to correlate with neurocognitive manifestations of the disorder. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Aug 18, 2025, 12:48 ET Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
Aug. 18, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced with deep sadness the passing of its Senior Vice President
More news about: Northwest Biotherapeutics
Aug 18, 2025, 12:37 ET Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
Aug. 18, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced with deep sadness the passing of its Senior Vice President
More news about: Northwest Biotherapeutics
Aug 18, 2025, 10:30 ET Beauty Devices Market Anticipated To Register 17.9% CAGR of During 2025-2031 by Increasing inclination toward beauty and wellness | The insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 18, 2025, 10:01 ET Hearing Aids Market Anticipated to Record US$ 45.68 billion by 2031 Due to Rising Geriatric Population | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 18, 2025, 09:00 ET Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
U.S. biotechnology company for its next-generation drug delivery platform, ACP (Advanced Cell Penetrating Peptide). Avixgen is a drug development company in which Dx&Vx holds a 66.2% stake. Through the licensing-out agreement, Avixgen grants the partner company, a U.S. biotechnology company,
More news about: Dx&Vx
Aug 18, 2025, 09:00 ET Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient in the fourth dose cohort has been treated in
More news about: Anixa Biosciences, Inc.
Aug 18, 2025, 08:30 ET High-Titer Lentivirus Solutions in 5 Days: Break Production Barriers for CGT, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 18, 2025, 08:30 ET Reshoring Biologics Development and Manufacturing for a Streamlined Path to IND, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 18, 2025, 08:30 ET Unlocking Oncology Pipelines with Next-Gen AI and Functional Data, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 18, 2025, 08:30 ET Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market
Aug. 18, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, provides a strategic update to shareholders highlighting the Company's
More news about: Klotho Neurosciences, Inc.
Aug 18, 2025, 08:00 ET STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME
Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced
More news about: Stealth BioTherapeutics Inc.
Aug 18, 2025, 08:00 ET Skyhawk Therapeutics Announces Strategic Collaboration with Merck to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders
payments, as well as tiered royalties on commercial sales. About Skyhawk TherapeuticsSkyhawk Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapies designed to modulate critical RNA targets and revolutionize patient
More news about: Skyhawk Therapeutics
Aug 18, 2025, 08:00 ET Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders
payments, as well as tiered royalties on commercial sales. About Skyhawk TherapeuticsSkyhawk Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapies designed to modulate critical RNA targets and revolutionize patient
More news about: Skyhawk Therapeutics
Aug 18, 2025, 08:00 ET ETHZilla Unveils New Brand Committed to Advancing Ethereum Treasury Strategy
top-tier DeFi founders, infrastructure pioneers and other ecosystem heavyweights. The Company, originally formed as an innovative biotechnology company, has also been evolving its business towards software enabled gaming and entertainment. In addition to its ETH treasury strategy
More news about: ETHZilla Corporation
Aug 18, 2025, 07:30 ET FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Aug 18, 2025, 06:21 ET KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
Sichuan Kelun Pharmaceutical Co., Ltd., specializing in the R&D, production, commercialization, and international collaboration of innovative biotechnology and small-molecule drugs. The Company focuses on addressing unmet clinical needs both globally and in China, with
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Aug 18, 2025, 06:00 ET Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Aug. 18, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy
More news about: SystImmune, Inc.
Aug 18, 2025, 02:03 ET Investor Alert: Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Class Action
securities between March 29, 2024 and June 27, 2025. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S.
More news about: Robbins LLP
Aug 17, 2025, 20:15 ET Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity
providing additional development updates moving forward." About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Aug 17, 2025, 08:01 ET GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,700 employees and has served more than 200,000 customers across 100 countries.
More news about: GenScript Biotech Corporation
Aug 15, 2025, 11:00 ET Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR | MarketsandMarkets™
maintained a preeminent position in the genomics market, capitalizing on a well-established customer base that includes leading pharmaceutical and biotechnology companies, genomic research institutions, and various government laboratories and hospitals. The firm possesses a dominant market share in the next-generation
More news about: MarketsandMarkets
Aug 15, 2025, 09:00 ET Cornerstone Research Advances Seven to Senior Vice President
fraud, product liability, and intellectual property matters. In addition to healthcare, her industry expertise includes agriculture, biotechnology, financial services, technology, and transportation. She formerly headed the firm's San Francisco office.About
More news about: Cornerstone Research
Aug 15, 2025, 08:30 ET Clinical Trial Application Success: CMC and Regulatory Insights from the US to Europe, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 15, 2025, 08:00 ET Origin Agritech Hosts Industry Summit in Zhengzhou, Strengthens Distribution Network with Over 700 Partners
the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company's
More news about: Origin Agritech Limited